IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Marcus KEEP et al. Conf.:

Appl. No.: Continuation of 09/787,861 Group: Unassigned

Filed: January 15, 2004 Examiner: Unassigned

For: NEUROIMMUNOPHILINS FOR SELECTIVE

NEURONAL RADIOPROTECTION

INFORMATION DISCLOSURE STATEMENT (SUBMISSION WITH CONTINUATION-IN-PART OR RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

January 15, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

Andrew D. Meikle, #32,868

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

ADM/RG/csm 0030-0208P

Attachment(s): \boxtimes PTO-1449(s)

□ References*

☐ Foreign Search Report

☐ Other:

* A copy of the Handschumaker et al. article is enclosed.

Form PTO-1449 ATTY. DOCKET NO. APPLICATION NO. 0030-0208P Continuation of 09/787,861 INFORMATION DISCLOSURE CITATION APPLICANT Marcus Keep, et al. IN AN APPLICATION (Use several sheets if necessary) FILING DATE GROUP January 15, 2004 1631 U.S. PATENT DOCUMENTS EXAMINER INITIAL CLASS DOCUMENT NUMBER DATE Kind NAME US 4,117,118 1978-09-26 Harri et al. US 5,116,816 1992-05-26 Dreyfuss et al. US 5,614,547 1997-05-25 Hamilton et al. US 5,648,351 1997-07-15 Kelly et al. US 5,654,332 1997-08-05 Armistead US 5,780,484 1998-07-14 Zelle et al. US 5,795,908 1998-08-18 Hamilton et al. US FOREIGN PATENT DOCUMENTS TRANSLATION Office DOCUMENT Kind COUNTRY DATE NUMBER МО 97/18828 1997-05-29 WO PCT A1 B1 0 184 162 1994-04-27 EPO OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Pellmar et al, Comments Toxicol., Vol. 2, No. 4, pp. 253-263 (1988). Bradley et al., Advances in Neurology, Vol. 56, pp. 341-353. Tatton et al., Ann. Neurol., Vol. 44, Suppl. 1, pp. S1324-S141 (Sept. 1998). Friberg, J. Neuroscience, Vol. 18, No. 14, pp. 5151-5159 (1998). Snyder et al., Neuron, Vol. 21, pp. 283-294 (1998). Ide et al, PubMed PMID 8938254 abstract of Neurosci. Lett., 204(3):157-160 (1996). Tokime et al, PubMed PMID 8710192 abstract of Neurosci. Lett., 206(2-3):81-84 (1996). Yagita et al, PubMed PMID 8913329 abstract of Life Sci., 59(19):1643-1650 (1996). Handschumacher et al., Science, New Series, Vol. 226, Issue 4674, pp. 544-547 (1984). EXAMINER DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.